Moleculin Biotech (MBRX)
NASDAQ:MBRX
Want to see MBRX full AI Analyst Report?
MBRX Stock Chart & Stats
$2.42
-$0.01(-0.56%)
At close: 4:00 PM EST
$2.42
-$0.01(-0.56%)
Day’s Range― - ―
52-Week Range$1.79 - $24.00
Previous CloseN/A
Volume63.82K
Average Volume (3M)2.74M
Market Cap
$14.89M
Enterprise Value-$6.76M
Total Cash (Recent Filing)$10.32M
Total Debt (Recent Filing)$185.00K
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Aug 19, 2026EPS Estimate
-1.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.96
Shares Outstanding5,336,350
10 Day Avg. Volume1,958,319
30 Day Avg. Volume2,738,732
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)2.61
Price to Sales (P/S)0.00
P/FCF Ratio-1.72
Enterprise Value/Market Cap-0.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit182.66
Enterprise Value/Ebitda0.23
Forecast
1Y Price Target
$16.00Price Target Upside561.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.11
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Non-cardiotoxic AnthracyclineDemonstrated lack of cardiotoxicity is a durable clinical differentiation for Annamycin versus traditional anthracyclines. This safety profile supports higher cumulative dosing, broader use in pretreated patients, and a structural competitive advantage that can expand market access and regulatory appeal over time.
Pivotal MIRACLE Trial ProgressAdvancing a pivotal adaptive Phase 2B/3 trial with encouraging interim metrics materially de-risks the program. A positive interim unblinding can accelerate regulatory discussions, support a registration path, and structurally improve commercialization prospects independent of short-term market moves.
Stronger IP ProtectionAdded patents extending exclusivity into 2040 strengthen long-term commercial exclusivity in Asia and globally. Durable IP protection enhances licensing leverage, supports future pricing strategies, and underpins the value of a successful clinical program across major markets.
Bears Say
Zero Revenue, Persistent Cash BurnThe company remains pre-revenue with sustained multi-year operating cash burn. Without product revenues, continuing losses force dependence on external financing; this structural cash gap elevates execution and dilution risk and constrains strategic optionality over the medium term.
Eroding Equity Base And Financing RiskA shrinking capital base reduces financial resilience if development requires more funding. Even with low debt, declining equity/assets raise vulnerability to adverse trial outcomes or delays, increasing the likelihood of dilution or onerous financing terms in future raises.
Limited Scale And Commercialization CapacityA very small workforce and R&D-centric model mean the company lacks built-in commercial infrastructure. To commercialize or scale globally it will need partners or significant investment, creating execution and dependency risk that persists beyond immediate trial milestones.
Moleculin Biotech News
MBRX FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was $1.79 and its highest was $24.00 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $14.89M.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Aug 19, 2026 which is in 80 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on May 15, 2026. The company reported -$3.54 earnings per share for the quarter, missing the consensus estimate of -$2.333 by -$1.207.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate is -1.54.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 5,336,350 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -$3.54 in its last earnings report, missing expectations of -$2.333. Following the earnings report the stock price went down -4.091%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in MBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Moleculin Biotech
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
MBRX Stock 12 Month Forecast
Average Price Target
$16.00
▲(561.16% Upside)
Technical Analysis
Ownership Overview
20.61% Insiders
0.56% Mutual Funds
1.41% Other Institutional Investors
77.16% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---